JP2006510669A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006510669A5 JP2006510669A5 JP2004559315A JP2004559315A JP2006510669A5 JP 2006510669 A5 JP2006510669 A5 JP 2006510669A5 JP 2004559315 A JP2004559315 A JP 2004559315A JP 2004559315 A JP2004559315 A JP 2004559315A JP 2006510669 A5 JP2006510669 A5 JP 2006510669A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- age
- patient
- group
- compound selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43140102P | 2002-12-06 | 2002-12-06 | |
| PCT/US2003/038678 WO2004052227A2 (en) | 2002-12-06 | 2003-12-05 | Superoxide dismutase mimics for the treatment of ocular disorders and diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006510669A JP2006510669A (ja) | 2006-03-30 |
| JP2006510669A5 true JP2006510669A5 (enExample) | 2006-08-24 |
Family
ID=32507723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004559315A Pending JP2006510669A (ja) | 2002-12-06 | 2003-12-05 | 眼障害および眼疾患の処置のためのスーパーオキシドジスムターゼ模倣物 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20060089343A1 (enExample) |
| EP (1) | EP1581212A4 (enExample) |
| JP (1) | JP2006510669A (enExample) |
| CN (1) | CN1717234A (enExample) |
| AU (1) | AU2003298917A1 (enExample) |
| BR (1) | BR0317026A (enExample) |
| CA (1) | CA2505608A1 (enExample) |
| MX (1) | MXPA05005240A (enExample) |
| WO (1) | WO2004052227A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2397067B (en) * | 2002-12-23 | 2005-05-11 | Destiny Pharma Ltd | Porphin & azaporphin derivatives with at least one cationic-nitrogen-containing meso-substituent for use in photodynamic therapy & in vitro sterilisation |
| GB2415372A (en) | 2004-06-23 | 2005-12-28 | Destiny Pharma Ltd | Non photodynamical or sonodynamical antimicrobial use of porphyrins and azaporphyrins containing at least one cationic-nitrogen-containing substituent |
| WO2006033734A2 (en) * | 2004-08-18 | 2006-03-30 | Sirion Therapeutics, Inc. | Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat opthalmic disorders |
| WO2006091796A2 (en) * | 2005-02-22 | 2006-08-31 | Acucela, Inc. | Compositions and methods for diagnosing and treating retinal diseases |
| MX2009011360A (es) | 2007-04-20 | 2010-02-12 | Acucela Inc | Compuestos derivados de estirenilo para tratar enfermedades y trastornos oftalmicos. |
| CA2690229C (en) | 2007-06-29 | 2013-10-29 | Acucela, Inc. | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders |
| WO2009045479A1 (en) | 2007-10-05 | 2009-04-09 | Acucela Inc. | Alkoxy compounds for disease treatment |
| JP5559701B2 (ja) * | 2008-01-30 | 2014-07-23 | エージェンシー フォー サイエンス，テクノロジー アンド リサーチ | イミダゾリウム及びイミダゾリニウム化合物で線維症及び癌を治療する方法 |
| WO2009123569A1 (en) * | 2008-03-31 | 2009-10-08 | Agency For Science, Technology And Research | Method for treating neurological disorders with imidazolium and imidazolinium compounds |
| US8598150B1 (en) | 2008-04-02 | 2013-12-03 | Jonathan R. Brestoff | Composition and method for affecting obesity and related conditions |
| US8987245B2 (en) | 2008-04-02 | 2015-03-24 | Jonathan R. Brestoff Parker | Composition and method for affecting obesity and related conditions |
| AU2010313249B2 (en) | 2009-10-30 | 2016-05-19 | Biojiva Llc | Alleviating oxidative stress disorders with PUFA derivatives |
| EP2433640B1 (en) | 2010-09-24 | 2020-01-15 | OmniVision GmbH | Composition comprising SOD, lutein and zeaxanthin |
| US10154983B2 (en) | 2011-04-26 | 2018-12-18 | Retrotope, Inc. | Neurodegenerative disorders and muscle diseases implicating PUFAs |
| CA2834342C (en) | 2011-04-26 | 2021-08-31 | Retrotope, Inc. | Impaired energy processing disorders and mitochondrial deficiency |
| DK2701697T3 (da) | 2011-04-26 | 2020-06-29 | Retrotope Inc | Oxidative nethindesygdomme |
| KR102110175B1 (ko) | 2011-04-26 | 2020-05-13 | 레트로토프 인코포레이티드 | Ｐｕｆａ 산화와 관련된 장애 |
| WO2013109991A1 (en) | 2012-01-20 | 2013-07-25 | Acucela Inc. | Substituted heterocyclic compounds for disease treatment |
| EP2911662A4 (en) * | 2012-10-25 | 2016-09-28 | Technion Res & Dev Foundation | METHOD OF TREATING A DISEASE |
| BR112015022041A2 (pt) | 2013-03-12 | 2017-07-18 | Acucela Inc | derivados substituídos de 3-fenilpropilamina para o tratamento de doenças e distúrbios oftálmicas |
| EP3950649A1 (en) | 2015-11-23 | 2022-02-09 | Retrotope, Inc. | Site-specific isotopic labeling of 1, 4-diene systems |
| KR20220143931A (ko) | 2020-02-21 | 2022-10-25 | 레트로토프 인코포레이티드 | 고도불포화 지방산 및 이의 유도체의 동위원소 변형을 위한 공정 |
| US12109194B2 (en) | 2021-02-05 | 2024-10-08 | Biojiva Llc | Synergistic combination therapy for treating ALS |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5252720A (en) * | 1989-03-06 | 1993-10-12 | Board Of Regents, The University Of Texas System | Metal complexes of water soluble texaphyrins |
| TW325997B (en) * | 1993-02-02 | 1998-02-01 | Senju Pharma Co | Pharmaceutical composition for preventing and treating retinal diseases |
| US6127356A (en) * | 1993-10-15 | 2000-10-03 | Duke University | Oxidant scavengers |
| US5994339A (en) * | 1993-10-15 | 1999-11-30 | University Of Alabama At Birmingham Research Foundation | Oxidant scavengers |
| US5798349A (en) * | 1994-03-14 | 1998-08-25 | The General Hospital Corporation | Use of green porphyrins to treat neovasculature in the eye |
| US6214817B1 (en) * | 1997-06-20 | 2001-04-10 | Monsanto Company | Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity |
| US6180620B1 (en) * | 1997-06-20 | 2001-01-30 | G.D. Searle & Co. | Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals |
| CA2309154C (en) * | 1997-11-03 | 2010-02-16 | Duke University | Substituted porphyrins |
| GB9817845D0 (en) * | 1998-08-17 | 1998-10-14 | Glaxo Group Ltd | Chemical compounds |
| ATE552260T1 (de) * | 1999-01-25 | 2012-04-15 | Nat Jewish Health | Substituierte porphyrine und deren therapeutische verwendung |
| AU2002312194B8 (en) * | 2001-06-01 | 2008-05-15 | Aeolus Sciences, Inc. | Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance |
-
2003
- 2003-12-05 CN CNA2003801041193A patent/CN1717234A/zh active Pending
- 2003-12-05 AU AU2003298917A patent/AU2003298917A1/en not_active Abandoned
- 2003-12-05 WO PCT/US2003/038678 patent/WO2004052227A2/en not_active Ceased
- 2003-12-05 US US10/534,791 patent/US20060089343A1/en not_active Abandoned
- 2003-12-05 EP EP03796677A patent/EP1581212A4/en not_active Withdrawn
- 2003-12-05 JP JP2004559315A patent/JP2006510669A/ja active Pending
- 2003-12-05 MX MXPA05005240A patent/MXPA05005240A/es unknown
- 2003-12-05 CA CA002505608A patent/CA2505608A1/en not_active Abandoned
- 2003-12-05 US US10/729,213 patent/US20040116403A1/en not_active Abandoned
- 2003-12-05 BR BR0317026-8A patent/BR0317026A/pt unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006510669A5 (enExample) | ||
| JP2008519047A5 (enExample) | ||
| JP2003503454A5 (enExample) | ||
| EE200300295A (et) | Kinuklidiinkarbamaadi derivaat, selle saamine ja kasutamine ravimi valmistamiseks, mis on ette nähtud respiratoorsete, kuseelundite või mao-soolte haiguste ravimiseks, ning seda sisaldav ravimkompositsioon | |
| CY1115719T1 (el) | Νεοι φαρμακευτικοι συνδυασμοι για τη θεραπεια νοσων των αναπνευστικων οδων | |
| JP2009526751A5 (enExample) | ||
| DE69918296D1 (de) | N-substituierte aminotetraline als neuropeptid y y5 rezeptor-liganden und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen | |
| JP2005537234A5 (enExample) | ||
| WO2008008433A3 (en) | Substituted acylanilides and methods of use thereof | |
| ATE482708T1 (de) | Behandlung von neovaskulären augenerkrankungen, wie z.b. maculadegeneration, angioiden streifen, uveitis und makulaödemen | |
| EP2301531A3 (en) | Combinations and modes of administration of therapeutic agents and combination therapy | |
| JP2007510667A5 (enExample) | ||
| ATE396967T1 (de) | (5-(2-hydroxy-4-chlorbenzoyl)valeriansäure und deren salze, und zusammensetzungen zur zuführung von wirkstoffen, die diese verbindungen enthalten | |
| JP2007537301A5 (enExample) | ||
| MXPA03006526A (es) | Composicion farmaceutica que contiene compuestos de aminoacetonitrilo y su uso para la preparacion de una composicion farmaceutica para el tratamiento de plagas endoparasitarias en animales. | |
| JP2008540528A5 (enExample) | ||
| DK1643999T3 (da) | Pyridoxamin til anvendelse ved behandlingen af diabetisk nefropati ved type 2-diabetes | |
| ATE491715T1 (de) | Oligoribonukleotide und verfahren zu deren anwendung bei der behandlung von fibrotischen leiden und anderen krankheiten | |
| JP2005517713A5 (enExample) | ||
| WO2007030944A3 (en) | Methods of cardioprotection using dichloroacetate in combination with an inotrope | |
| Club et al. | Autism Spectrum Disorders | |
| DE602005020113D1 (de) | Verfahren zur behandlung von akuten rhinosinusitis | |
| JP2006510659A5 (enExample) | ||
| ATE344662T1 (de) | Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen | |
| JP2006527741A5 (enExample) |